Personalis, Inc. (PSNL) — Stock Valuation & Research

Personalis, Inc. operates globally as a specialized cancer genomics firm. The company delivers advanced sequencing and data analysis capabilities, primarily supporting the development of novel cancer treatments and facilitating extensive genetic research initiatives. Central to their offerings is the NeXT Platform, which enables detailed data analysis of tumors and their surrounding immune microenvironments, even from small tissue or plasma samples. This platform encompasses several specialized solutions: ImmunoID Next for tissue-based tumor profiling; NeXT Liquid Biopsy for plasma analysis;…

PSNL key statistics

Explore PSNL's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.